{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:39:04Z","timestamp":1790631544233,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40265-026-02313-1","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T03:26:55Z","timestamp":1775532415000},"page":"957-961","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tradipitant: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-7831","authenticated-orcid":false,"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"issue":"41","key":"2313_CR1","first-page":"687","volume":"115","author":"A Koch","year":"2018","unstructured":"Koch A, Cascorbi I, Westhofen M, et al. The neurophysiology and treatment of motion sickness. Dtsch Arztebl Int. 2018;115(41):687\u201396.","journal-title":"Dtsch Arztebl Int"},{"key":"2313_CR2","doi-asserted-by":"publisher","first-page":"1550670","DOI":"10.3389\/fneur.2025.1550670","volume":"16","author":"VM Polymeropoulos","year":"2025","unstructured":"Polymeropoulos VM, Kiely L, Bushman ML, et al. Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled study. Front Neurol. 2025;16:1550670.","journal-title":"Front Neurol"},{"key":"2313_CR3","unstructured":"Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals announces FDA approval of NEREUS\u2122 (tradipitant) for the prevention of vomiting induced by motion: a historic scientific milestone in the prevention of motion sickness [media release]. 30 Dec 2025. http:\/\/www.vandapharma.com."},{"key":"2313_CR4","unstructured":"Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals clinical development pipeline. 2026. https:\/\/www.vandapharma.com\/pipeline\/. Accessed 20 Feb 26."},{"key":"2313_CR5","unstructured":"Vanda Pharmaceuticals Inc. NEREUS\u2122 (tradipitant): US prescribing information. 2025. https:\/\/www.fda.gov\/. Accessed 20 Feb 2026."},{"key":"2313_CR6","unstructured":"Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals acquires rights to NK-1 receptor antagonist from Eli Lilly and Company [media release]. 16 Apr 2012. http:\/\/www.vandapharma.com."},{"key":"2313_CR7","unstructured":"United States Patent and Trademark Office. Patent US10821099B2: use of tradipitant in motion sickness. 2019. https:\/\/patents.google.com\/patent\/US10821099B2. Accessed 20 Feb 2026."},{"key":"2313_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.563373","volume":"11","author":"VM Polymeropoulos","year":"2020","unstructured":"Polymeropoulos VM, Czeisler M, Gibson MM, et al. Tradipitant in the treatment of motion sickness: a randomized, double-blind, placebo-controlled study. Front Neurol. 2020;11:563373.","journal-title":"Front Neurol"},{"issue":"12","key":"2313_CR9","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1016\/j.cgh.2024.01.005","volume":"22","author":"JL Carlin","year":"2024","unstructured":"Carlin JL, Polymeropoulos C, Camilleri M, et al. The efficacy of tradipitant in patients with diabetic and idiopathic gastroparesis in a phase 3 randomized placebo-controlled clinical trial. Clin Gastroenterol Hepatol. 2024;22(12):2506\u201316.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2313_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1053\/j.gastro.2020.07.029","volume":"160","author":"JL Carlin","year":"2021","unstructured":"Carlin JL, Lieberman VR, Dahal A, et al. Efficacy and safety of tradipitant in patients with diabetic and idiopathic gastroparesis in a randomized, placebo-controlled trial. Gastroenterology. 2021;160(1):76-87.e4.","journal-title":"Gastroenterology"},{"key":"2313_CR11","unstructured":"Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals reports positive results for tradipitant in preventing GLP-1 induced nausea and vomiting [media release]. 17 Nov 2025. http:\/\/www.vandapharma.com."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02313-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02313-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02313-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:40:15Z","timestamp":1778856015000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02313-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2313"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02313-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent to publish, availability of data and material, code availability"}}]}}